More Evidence that Walking is Good for the Brain

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

For the second time in as many months, a major study has shown that a regular walk leads to better brain health.

We recently posted this analysis of data from the Cardiovascular Health Study - Cognition Study showing that regular walking over a period of years preserved brain volume. Now, further analysis of the same data set was presented at the Radiological Society of North America showing that cognition was preserved among walkers at a significantly better level than among a sedentary group.

The data are compelling; a regular daily walk is good for you.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Promising Alzheimer's Drugs on the Horizon

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

While we often emphasize the importance of non-pharmacologic therapies for treating Alzheimer's disease, more effective drugs could have an enormous, positive impact on our ability to combat its looming threat. A such, here is a brief summary of three of the most promising treatments in the FDA pipeline.

All three of these agents operate on the amyloid hypothesis which holds that, an accumulation of beta-amyloid, a naturally occurring protein in the brain, is the cause of Alzheimer's disease. While two recent trials on agents developed to reduce the production of beta-amyloid have failed, these three are intended to remove beta-amyloid from the brain.

Two similar drugs are Solanezumab and Bapineuzumab. Both are anti-bodies that attach to amyloid and then carry it away when they are flushed out of the body by the immune system. Solanezumab most likely operates outside of the brain which may lead to better tolerance than Bapineuzumab, which had more evidence of efficacy in its earlier stage studies. Each trial is well underway and the first published data should be forthcoming in late 2011 or early 2012.

Gammagard is Baxter's intraveneous immunoglobulin or IVIG, which also relies on removing amyloid through immune system mechanisms. IVIG is already on the market but with no approved claims for treating Alzheimer's disease.

There are certainly other approaches in the pipeline, some of which may bring better results in a shorter time frame than the three highlighted here. But these seem to have the strongest theoretical underpinnings and have bred the most optimism in the scientific community.
-------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Treating Alzheimer's Disease Without Drugs

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

One of the common themes in this blog is that "current treatment for Alzheimer's disease is better than many headlines indicate".

We write this because the argument against treatment efficacy is almost always framed through the narrow lens of drug-based interventions when, in reality, drugs are only one part of the most effective approach. A robust approach includes management of risk factors like smoking and excessive drinking, controlling co-morbid conditions such as diabetes and hypertension, proper diet, physical exercise, and both social and intellectual engagement.

We also point out that many reports of poor treatment efficacy are based on studies of Alzheimer's patients in whom the disease is too far progressed, and the brain too ravaged, for treatment to have a fair chance at working.

There is an additional area of treatment that has shown impressive efficacy and should be emphasized as well; it is psychosocial interventions. These include care-giver education, structured communication techniques, home safety, family counseling, and problem resolution. The results have been clear; caregivers who know what to expect and how best to deal with problems as they emerge, are less stressed, less depressed, and more effective in giving care. The result is healthier patients who maintain higher quality of life and a prolonged ability to avoid institutionalized care.

The Huffington Post has a great summary today of this approach and I encourage all readers to click through and to share this with their interested peers.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Physical Exercise and Genetic Risk of Alzheimer's Disease

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

It has been well established that certain genes confer a higher risk for, but not a certain correlation with, Alzheimer's disease. It has also been well established that physical activity confers many health benefits including better flow of oxygen-rich blood to the brain and higher cognitive function.

Now, a study from the University of Wisconsin, Milwaukee, has looked at the benefits of physical exercise on those subjects with a specific, genetic, predisposition to Alzheimer's. As we would have hoped, the benefits of the physical activity seem to translate to this "at-risk" group as well.

The full publication on this study has not yet been released but the methodology was straight forward. Reearch subjects were separated into a "physically active" group and a "sedentary" group and brain activity was measured with functional MRI. According to the pre-publication press, there was no difference in brain activity in the hippocampul region (where short-term memory is processed) between those with a genetic risk for Alzheimer's and those without it.

This suggests that, even for those with a genetic predisposition to the disease, physical activity might be beneficial in delaying the onset or slowing the progression of Alzheimer's, just as it is for the rest of the population with a more favorable genetic profile.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Better View of the Brain

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

The enormous complexity of the brain makes understanding how it works, and how diseases affect its function, a daunting challenge. This challenge has been exacerbated by the microscopic scale of neurons and synapses, which makes it nearly impossible to gather information visually.

Now, researchers at Stanford University have developed a method for staining thin slices of brain tissue, capturing a series of high resolution images, and then stitching the images together to create a visual model of brain structure. Their paper on the method is published this week in Nature and the photo below shows the level of synaptic detail that their approach renders.

This is pretty exciting as it could greatly improve our ability to inspect brain tissue and to understand brain function; both of which could play a role in accelerating our understanding of the field.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Misplaced Moral Argument about Predicting Alzheimer's

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

When following the press in the brain health space, it is very common to find well-written opinion letters and perspective pieces about the moral dilemma of predicting Alzheimer's disease in healthy adults. Common headlines vary around the "would you want to know" or "would you take the test" theme. The crux of the argument is that, with no cure, we should not bother predicting the disease and revealing such a tragic fate.

In a nutshell, these are the usual defenses:
  • Predictions allow vigilant monitoring and timely intervention when symptoms appear which leads to better treatment.
  • Predictions allow for financial, legal, and spiritual preparation for end of life.
  • Predictions identify important research subjects who can greatly improve scientific efforts to develop new treatments by volunteering for trials.
There are other arguments but those are the most common and most compelling justifications.

The purpose of this post is neither to condemn nor condone the notion of predicting Alzheimer's disease but to point out how often the moral debate is misplaced. For predictive approaches, like genetic tests, I say let the debate rage. However, for identifying approaches, those that indicate with certainty if a person has Alzheimer's pathology that has not yet progressed to a stage producing obvious symptoms, then the whole notion of "prediction" is misplaced.

But the moral debaters do not respect this important difference between predicting the disease and identifying the disease. People who have it, have it. And when they present to a physician and complain of cognitive difficulties, they are asking their physician to figure out the cause of the problem and treat it as best as possible. No moral dilemma; these people want to know.

Remember, everyone has the right to not visit their doctor and not investigate emerging cognitive problems. Those who want to actively manage their health should be allowed and those who wish to remain ignorant have rights as well.

Soon, we will have the ability to identify Alzheimer's pathology with a PET scan which will enable earlier and more accurate diagnoses. In the not too distant future, we will likely have a spinal fluid test (followed by a blood test) that will accurately diagnose Alzheimer's disease at even early stages through more cost effective means. These are great steps forward and there is no moral or ethical downside to gaining these important clinical abilities.

Predicting Alzheimer's disease is a topic worthy of moral debate; identifying the disease is a categorically constructive step in the right direction.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

Non-Clinical Benefits of Early Detection of Alzheimer's Disease

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

In this short video from PBS, the National Alzheimer's Association's Medical Director, William Thies summarizes the non-clinical benefits of getting an early diagnosis of Alzheimer's disease.

He doesn't touch on the emerging evidence that treatment, even with currently approved medications, may also have greater benefits at an earlier stage of disease progression when the brain is still quite healthy. The extent of such treatment benefits is generally moderate but, for some patients, it can be quite meaningful.

William Thies, Ph.D., Chief Medical and Scientific Officer, Alzheimer’s Association

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

Alzheimer's Researchers Need Volunteer Subjects

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

We all agree; rapid scientific advance in the field of Alzheimer's disease will be the only way to avoid a joint crisis of declining senior health and an underfunded public health system in the coming years.

One barrier to such rapid advance is completely within our control. It requires no brilliant insight or penetrating scientific discovery; it merely requires volunteers.

Enrolling research subjects into the many ongoing trials, and the many new trials expected to open in the coming years, is a timely process. In fact, the enrollment stage of a study can take years. This is a terrible waste of time in the race to save the generation that is now entering the high-risk years for Alzheimer's disease. We need to do better.

The National Alzheimer's Association has launched the Trial Match program to help interested volunteers find a study that might be right for them. I encourage you to share this with anyone you think might benefit from the information.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

What Next for PET Imaging and Alzheimer's Diagnosis?

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

Last week we noted here that Mayo Clinic had named certain bio-markers, specifically those agents that bind to amyloid plaques in the brain and become visible with a PET scan, as the most important medical innovation of the coming year.

Such bio-markers may help diagnose Alzheimer's disease with more certainty than current methods. However, many experts correctly point out that, down the road, cheaper and more practical tests based on blood or cerebral spinal fluid samples, might offer equal benefits in a more pragmatic approach. In fact, changing protein levels in the blood and spinal fluid are likely, according to current theories, to show changes prior to plaque formation in the brain and therefore, might offer even earlier diagnosis than PET scans.

Interestingly, Eli Lilly announced yesterday that they are acquiring Avid Radio Pharmaceuticals, the maker of the PET tracer agent that is likely to be the first to gain FDA approval in early 2011. Given an acquisition price of up to $800 million (depending on achievement of certain milestones), for a company with no sales, it is safe to say that big pharma is sold on the value of diagnosing Alzheimer's disease with PET imaging.

The benefits of using bio-markers and PET imaging to diagnose AD, to detect changes in the brain during research, and to evaluate the effect of drugs in clinical trial, are all positive steps in our collective battle to reign in this terrible disease. But I am looking forward to even bigger steps and better solutions that seem to be following closely behind this exciting advance.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.

Diagnosing Alzheimer's with PET Imaging

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

The Mayo Clinic has concluded its 2010 Medical Innovation Summit and released it's annual list of top Medical Innovations.

Coming in at number 1 on their Top 10 list is: New molecular imaging biomarker for early detection, prevention and treatment of Alzheimer's disease. Specifically, they are referring to AV-45, a radioactive agent developed by Avid Radiopharmaceuticals.

This science has been under development for quite some time and is expected to receive FDA approval in early 2011. The concept is to inject a tracer agent into the blood stream that will make it's way to the brain, bind with amyloid plaques, and light up in a PET scan. This will make the presence of amyloid in the brain more visible.

Since amyloid is a key pathological indicator (if not the cause) of Alzheimer's disease, gaining an understanding of amyloid load in the brain is useful in several regards. It can indicate the presence of AD pathology at an early stage, even before major cognitive deficits have emerged and could allow for earlier detection and timely intervention against this progressive disease process. It could be useful in measuring treatment effects which could accelerate clinical trials and bring better drugs to market more rapidly. And finally, it could potentially be used in identifying preventative agents that block or reverse the build-up of amyloid in the brain.

Similar technologies are also under development from GE and Bayer and will likely make important contributions in the global battle to thwart Alzheimer's disease in the coming decade.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Alzheimer's and Fish Oil

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

If you stay attuned to news about Alzheimer's disease, you have likely seen the coverage of a study published this week in the Journal of the American Medical Association concluding that fish oil (or the omega-3 fat commonly known as DHA), has no benefit for Alzheimer's patients.

This was a well done study on more than 400 patients and the results were clear. However, as is often the case, readers of the press are advised to interpret specific scientific findings within their specific context, while being careful not to casually generalize the conclusions.

In this case, please keep in mind that the "no benefit" conclusion was drawn with regards to Alzheimer's patients. As we know, the current definition of Alzheimer's disease (although it is evolving) requires "dementia", which means that the subjects in this study had advanced pathology and significant brain damage with extensively impaired cognition. Given that degraded state of the brain, it's really not a surprise that fish oil supplements showed no improvement in cognition.

More importantly, this conclusion should not be generalized as meaning that previously well-established benefits of fish oil have been repudiated. The benefits shown in numerous epidemiological studies have shown that diets rich in omega-3 fatty acids reduce the risk of Alzheimer's disease.

In other words, once you have brain damage due to Alzheimer's disease, it is probably too late for fish oil to benefit your cognition. But earlier, while your brain is still healthy, omega-3 fats probably do have important benefits and likely reduce the risk of Alzheimer's down the road.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

5 Reasons Why Alzheimer's Awareness Matters More Than You Think

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

More so than with any other major disease, our near-term progress in the battle against Alzheimer’s will be determined largely by our ability to improve awareness about several aspects of this encroaching threat.

Summarized here are five reasons why greater awareness about Alzheimer’s disease, and a deeper public understanding of risks and prevention strategies, will play a key role in the nation’s ability to triumph against the prospect of a devastating AD epidemic.

1. Low Awareness drives higher medical costs

In this important but often overlooked regard, higher awareness and a better understanding of symptoms will benefit the vast majority of people who do not have Alzheimer’s disease (AD).

While AD is a worrisome topic, we have reached a point where the general level of education and awareness about the disease is high enough to induce worry, but not high enough to eliminate “unnecessary” worry. As a result, we are seeing a rise in expensive medical evaluations and increased costs of care driven by patients who are perfectly healthy.

In general, the public knows two things about AD. They know it is a debilitating disease with no cure, and they know that memory loss is a common symptom. That’s enough information to create a lot of angst in an aging population but a little more information would bring some needed relief.

For example, not every memory lapse is like every other, and many, if not most, are completely benign with no underlying medical cause. Furthermore, even those memory lapses that are related to a medical condition are often caused by some easily treatable problem.

INCREASE YOUR AWARENESS:
Here are a few things to know and to share with your social networks.

Memory loss can be caused by many common and treatable ailments including, but not limited to:
  • thyroid disorders
  • depression
  • vitamin deficiencies
  • medications (both prescription and over the counter)
  • anxiety
  • poorly controlled diabetes
Every instance of forgetfulness is not akin to a diagnosis of AD and not all memory lapses are equal:
  • Failing to store information for later recall when we are stressed or distracted is most likely a sign of overload than of a serious medical condition.
  • Taking longer to recall names as we age is a natural part of slower information processing in an older brain.
  • Forgetting where you parked at the mall is probably more like the rule than the exception.
Repeating a question or a story within a short time and not remembering the first instance is the kind of memory loss that should prompt a discussion with your physician.

2. Awareness facilitates timely medical intervention and better treatment outcomes


As discussed above, understanding the difference between worrisome signs and those that are less concerning can help the public make better decisions about if and when to speak with a physician. But there are other facets of increased awareness that will also facilitate earlier, proactive behavior that results in earlier medical intervention and better treatment results.

Specifically, knowing that treatment is more effective than is commonly reported in the press will drive more people to their physicians at early stage of symptoms before irreparable brain damage has occurred.

INCREASE YOUR AWARENESS: Here is an important perspective to keep in mind when you read about ongoing studies of treatment efficacy:

Many studies on drug efficacy have shown minimal treatment effect for the primary class of Alzheimer’s drugs (cholinesterase inhibitors) approved for sale in the USA. However, it should be understood that while the AVERAGE treatment effect is fairly moderate, some patients respond better than others. The average is comprised of a range of outcomes from better to worse and it is important to remember that no one knows in advance which patients will benefit more and which will benefit less.

More importantly, studies focused on isolating the effect of pharmaceutical therapy obscure the effect of a more robust treatment regimen that includes physical exercise, a healthy diet, proper control of hypertension and diabetes, avoidance of other medications that impair cognition and function, ongoing intellectual stimulation, and structured social engagement. Such a full regimen has demonstrated superior treatment effects than drug therapy alone in a meaningful number of patients. There is growing evidence that this is especially true when treatment begins early in the disease process.


While you should not be overly optimistic about currently approved treatments, you should not be overly discouraged by reports that drugs alone are not effective. In the real world, doctors prescribe drugs as one part of a more comprehensive treatment plan and, in some instances, AD progression can be meaningfully delayed.


3. Awareness erodes stigma and further enables timely medical intervention

Another major barrier to early intervention, aside from the nihilistic perceptions about treatment efficacy discussed above, is stigma. In fact, research shows that many people feel a sense of shame or embarrassment associated with a diagnosis of AD. This promotes denial and serves as an obstacle to early diagnosis and treatment.

However, research also shows that most stigmatizing topics can be brought into the open and can shed their embarrassing nature through education and discussion. Awareness campaigns generate discussion, which breeds familiarity and reduces stigma. In this regard, awareness is a direct path to openness, dialogue, information exchange, proactive management of symptoms, and professional medical intervention at the earliest possible stages.

INCREASE YOUR AWARENESS:
Consider these facts and then be sure your mind and your heart are both open to the plight of those facing Alzheimer’s disease.
  • More than 1 out of every 2 Americans now knows someone with Alzheimer’s disease.
  • The risk of getting Alzheimer’s disease is low until about age 65 then doubles every five years.
  • At age 85, the risk of AD is nearly 50%.

4. Awareness and management of risk factors can lower incidence of Alzheimer's disease

While it is true that AD remains poorly understood and difficult to treat, an enormous amount of research and new learning has been achieved in the last decade. We now recognize several risk factors that increase the likelihood of getting the disease and a few others that reduce the risk. The best news is that many of the risk factors are completely within our control and lend themselves to active management.

Gaining a clear understanding of how to reduce risks for AD can sometimes require careful discernment between sound science and commercial hype. In this regard, awareness and education are critical components of an effective strategy for maintaining cognitive health through risk factor management.

INCREASE YOUR AWARENESS:
Here is a brief summary of well-established risk factors that should be discussed with your physician to establish a risk management strategy:

Cardiovascular conditions increase the likelihood of Alzheimer’s disease and should be actively managed to mitigate the risk:
  • Obesity
  • High Cholesterol
  • Hypertension (High-blood pressure)
Diabetes, especially when poorly controlled, increases the risk for Alzheimer’s disease. If you are diabetic, work with your physician to keep it under optimal control.

Substance abuse and heavy smoking are correlated with higher risk for Alzheimer’s disease providing one more important reason to seek any help you need in breaking a reliance on tobacco, drugs and alcohol.

There are also some manageable factors that reduce your risk for Alzheimer’s disease including proper diet, physical activity, and ongoing social and intellectual engagement. Gaining these benefits is as easy as being aware and making good life style decisions.

5. Awareness accelerates scientific progress
One of the challenges preventing faster progress in understanding Alzheimer’s disease is the availability of subjects who volunteer for research studies. In this highly active field, there are studies seeking healthy adults who do not have Alzheimer’s, others that seek adults with various levels of memory loss, and still other studies enrolling subjects who have been diagnosed with the disease.

Participating in a study is a commitment to pursue a regular regimen of therapy and a closely monitored protocol of care. However, it is also a commitment by the investigating physician to provide a defined level of care, which is in many cases, a higher level of care than you might get from your usual physician.

Often times, a study provides an opportunity to be treated with experimental drugs that are otherwise unavailable. Because drug development is a low-probability endeavor, early stage agents are more likely to be ineffective than they are to have a significant health benefit. However, depending on a person’s current prognosis, the opportunity to try an experimental treatment might be appealing.

In any event, each study contributes to our overall knowledge and moves us one step closer to the solution we all seek. Volunteers who participate in these studies keep the wheels of scientific progress moving.

INCREASE YOUR AWARNEESS: Learn about ongoing trials and stay abreast of new studies as they are launched. After all, one out of every two of us knows someone who might be interested.

Resources for learning about FDA trials:
  • Alzheimer’s Association Trial Match
  • NIH Alzheimer’s Education and Referral Center (ADEAR)
It is easy to overlook “awareness” as an important part of the solution to the Alzheimer’s problem. This is especially true given the clear need for better treatment. However, a little reflection on the benefits of awareness, weighed against the relative ease with which we can spread information today, shows the massive benefits of greater awareness.

Awareness matters. Please do your part to increase awareness by sharing this article with your online social networks.

Presidential Proclamation on National Alzheimer's Awarness Month

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

You will likely see an increase in Alzheimer's coverage in the press this month as National Alzheimer's Awareness Month has begun.

Tomorrow, I will post my take on why I think Awareness is extremely important and, in fact, under-rated as an effective strategy toward real progress in the fight against this disease. In the meantime, I think this presidential proclamation from the White House makes a pretty compelling case about the need to pay attention to Alzheimer's disease.

Follow Brain Today on Twitter

--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share button below to spread this educational message as widely as possible.